Bioventus Inc

NASDAQ:BVSUnited States

Today

Show headlines and story abstract

• -- Earnings Flash (BVS) BIOVENTUS Reports Q3 Revenue $139M, from 1 hour ago by MT Newswires

  1 hour ago by MT Newswires
  Companies Mentioned: BVS
  07:34 AM EST, 11/05/2024 (MT Newswires) -- ...

• -- Earnings Flash (BVS) BIOVENTUS Posts Q3 EPS $0.06, from 1 hour ago by MT Newswires

  1 hour ago by MT Newswires
  Companies Mentioned: BVS
  07:33 AM EST, 11/05/2024 (MT Newswires) -- ...

• Bioventus Reports Third Quarter Financial Results, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: BVS
  Nine Months Net Loss EPS from Ended September Operating Operating Continuing Continuing 30, 2023 Gross Profit Expenses(a) R&D Loss Operations Operations(k) ------------ ------------ ---------- ------------ -------------- ----------------- Reported GAAP measure $241,892 $ 314,598 $ 10,184 $(82,890) $(113,540) $ (1.45) Reported GAAP margin 64.2% (22.0%) Depreciation and amortization(b) 38,146 6,740 14 44,900 44,900 0.57 Acquisition and related costs(c) -- 4,047 -- 4,047 4,047 0.05 Restructuring and succession charges(e) -- 911 -- 911 911 0.01 Financial restructuring costs(f) -- 7,065 -- 7,065 7,065 0.09 Impairment of assets(g) -- 78,615 -- 78,615 78,615 1.01 Loss on disposal of a business(h) -- 1,317 -- 1,317 1,317 0.02 Other items(i) -- 6,262 1,286 7,548 7,548 0.10 Tax effect of adjusting items(j) -- -- -- -- (31,790) (0.47) ------- ----------- ------ ------- -------- --- ------- Non-GAAP measure $280,038 $ 209,641 $ 8,884 $ 61,513 $ (927) $ (0.07) ------- ----------- ------ ------- -------- --- ------- Non-GAAP margin 74.3% 16.3% ======= ======= Non-GAAP Non-GAAP Non-GAAP Non-GAAP Non-GAAP Adjusted EPS Gross Operating R&D Operating Net Loss Continuing Margin Expenses Income Continuing Operations Operations (a) The "Reported GAAP Measure" under the "Operating Expenses" column is a sum of all GAAP operating expense line items, excluding research and development. (b) Includes for the three months ended September 28, 2024 and September 30, 2023 and the nine months ended September 28, 2024 and September 30, 2023, respectively, depreciation and amortization of $10.2 million, $11.5 million, $31.3 million and $38.1 million in cost of sales and $2.1 million, $2.3 million, $5.9 million and $6.8 million in operating expenses presented in the consolidated statements of operations and comprehensive loss. (c) Includes acquisition and integration costs related to completed acquisitions and changes in fair value of contingent consideration. (d) Costs incurred as a result of certain shareholder litigation unrelated to our ongoing operations. (e) Costs incurred were the result of adopting restructuring plans to reduce headcount, reorganize management structure, and consolidate certain facilities. (f) Financial restructuring costs include advisory fees and debt amendment related costs. (g) Represents a non-cash impairment charge for intangible assets solely attributable to our Advanced Rehabilitation Business in 2024 due to our decision to divest the business. Activity in 2023 relates to the non-cash impairment charge attributable to our divested Wound Business. (h) Represents the loss on disposal of the Wound Business. (i) Other items primarily includes charges associated with strategic transactions, such as potential acquisitions or divestitures and a transformative project to redesign systems and information processing. Divestiture costs related to our Advanced Rehabilitation Business, including transactional fees, totaled $1.6 million and $3.5 million during the three and nine months ended September 28, 2024, respectively. Strategic transactions and transformative project expenses amounted to $0.4 million and $1.3 million, respectively, for the nine months ended September 28, 2024. Strategic transactions and divestiture expenses totaled $0.7 million and $4.2 million for the three and nine months ended September 30, 2023, respectively. Transformative project costs incurred amounted to $1.0 million and $3.1 million during the three and nine months ended September 30, 2023, respectively. We incurred $1.2 million in costs during the nine months ended September 30, 2023 related to MOTYS. Other items for the nine months ended September 30, 2023 also includes severance costs totaling $2.3 million related to the transition of our executive leadership and the reversal of equity compensation expenses totaling $3.8 million related to the transition of our executive leadership. (j) The three and nine months ended September 28, 2024 includes a tax impact of $0.5 million and $8.7 million, respectively, related to the impairment of assets. The nine months ended September 30, 2023 includes a $15.3 million tax impact related to the impairment of assets. An estimated tax impact for the remaining adjustments to Non-GAAP Net Income (Loss) was calculated by applying a rate of 25.1% to those adjustments for the three and nine months ended September 28, 2024 and September 30, 2023. (k) Adjustments are pro-rated to exclude the weighted average non-controlling interest ownership of 19.5% and 20.0%, respectively, for the three and three and nine months ended September 28, 2024 and September 30, 2023.
  

• Press Release: Bioventus Reports Third Quarter Financial Results, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: BVS